Overview
A graduate of Universidad Nacional de Colombia, Dr. Mosquera completed his residency and Surgical Pathology Fellowship at Rush University Medical Center in Chicago, IL, followed by Fellowships in Genitourinary Pathology and Translational Research at Brigham and Women’s Hospital in Boston, MA.
Dr. Mosquera has co-authored over 100 peer-reviewed publications and serves as Section Editor in Precision Medicine for Archives of Pathology & Laboratory Medicine. He is lead pathologist in validation studies of the Early Detection Research Network (EDRN), and Director of Pathology at the Englander Institute for Precision Medicine of WCM-NYP.
Highlights
- 1The American journal of surgical pathology · 2023
- 2The American journal of surgical pathology · 2022
- 3Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2024
Publications
Funding
Active
3 grants- Co-IHHSN261201500003IPersonalized in vitro models to advance precision health equityNational Cancer Institute · 2024–2027 · via Leidos Biomedical Research
- Co-I24CHAL11Development and optimization of CEACAM5-targeted alpha emittersProstate Cancer Foundation · 2025–2027
- PIW81XWH-21-1-0762Novel Complex Structural Variants And Epigenetic Alterations Link The Genomes Of Prostate Cancer In African Americans With Outcome Disparity.U.S. Department of Defense · 2021–2026
Completed grants (13)
- MPINYGC 204878-03Unraveling the landscape of homologous recombination deficiency in patients with breast and prostate cancer across the African diaspora in NYCNew York Genome Center Inc. · 2020–2024
- KPP50CA211024-05Weill Cornell Medicine (WCM) SPORE in Prostate CancerNational Cancer Institute · 2017–2023
- KPHHSN26100008Personalized in vitro models to advance precision medicineNational Cancer Institute · 2019–2023 · via Leidos Biomedical Research
- Co-IR37CA229861-01A1Cell-of-Origin Footprints of Passenger Mutations in Human Lung CancerNational Cancer Institute · 2021–2023
- Sub-PIWCMCQ 227485-01Differences in methylation profiles of prostate cancer (PCa) patients with different genetic ancestryQatar National Research Fund · 2022–2022 · via Weill Cornell Medical College/QatarNo publications yet
- Sub-PIU24CA086380-19San Antonio Center for Biomarkers of Risk for Prostate Cancer (SABOR)National Cancer Institute · 2017–2022 · via University of Texas Health Science Center at San AntonioNo publications yet
- PIR01CA184712-05Precision Medicine Approach to Prostate Cancer Active SurveillanceNational Cancer Institute · 2014–2021
- PIWCMC 203235-01High dimensional characterization of cancer immune microenvironment by imaging mass cytometryWeill Cornell Medical College · 2020–2021
- KPR01CA179100-02Mechanistic Insights Underlying ERG-Induced Taxane Resistance in Castration-Resistant Prostate CancerNational Cancer Institute · 2014–2020
- PIBP 192599-01BioPharma Alliance Agreement between WCM (Dr. Juan Miguel Mosquera) and Personal Genome Diagnostics (PGDx) - Phase IIPersonal Genome Diagnostics · 2019–2019Contract
- KPU01CA086402-15S2EDRN: Biomarkers and Clinical Parameters Associated With Gleason Score UpgradingNational Cancer Institute · 2014–2016 · via University of Texas Health Science Center at San Antonio
- KPU01CA162148-04Systemic Genetic Characterization of African American Prostate CancerNational Cancer Institute · 2012–2016 · via Dana-Farber Cancer Institute
- KPU01CA111275-10Michigan/Cornell EDRN BDL: A Systems Biology Approach to the Development of Cancer BiomarkersNational Cancer Institute · 2010–2015 · via University of Michigan
Clinical research
Active
1 study- PINovel complex structural variants and epigenetic alterations link the genomes of African ancestry prostate cancer with outcome disparityWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2021)
News mentions
- Tumor Organoid Tech Advances Toward a Sci-Fi FutureJuly 20, 2026
Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators.
- Whole-Genome Sequencing May Optimize PARP Inhibitor UseJanuary 12, 2026
A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
- Mapping the Evolution of Urinary Tract Cancer CellsMarch 18, 2024
Researchers at Weill Cornell Medicine have performed the most comprehensive analysis to date of cancer of the ureters or the urine-collection cavities in the kidney, known as upper tract urothelial carcinoma (UTUC).
- Deciphering the Male Breast Cancer GenomeMarch 4, 2024
Male breast cancer has distinct alterations in the tumor genome that may suggest potential treatment targets, according to a study by Weill Cornell Medicine investigators.
- Germline Whole-Exome Sequencing Reveals Potential New Treatment Opportunities in Bladder CancersDecember 8, 2020
A significant percentage of patients with urothelial cancers have inherited gene variants that drive the progression of these cancers, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.
Show 1 more mention
- Weill Cornell Medicine Community Celebrates Diversity with Annual AwardsJuly 22, 2020
Weill Cornell Medicine is honoring 15 faculty members, trainees, students and staff this year for their outstanding service and leadership in promoting diversity at the academic medical institution.